These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. The management impact of Kulkarni M; Hughes S; Mallia A; Gibson V; Young J; Aggarwal A; Morris S; Challacombe B; Popert R; Brown C; Cathcart P; Dasgupta P; Warbey VS; Cook GJR Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):674-686. PubMed ID: 31872280 [TBL] [Abstract][Full Text] [Related]
11. The role of ( Yilmaz U; Komek H; Can C; Altindag S Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696 [TBL] [Abstract][Full Text] [Related]
13. The use of Meredith G; Wong D; Yaxley J; Coughlin G; Thompson L; Kua B; Gianduzzo T BJU Int; 2016 Oct; 118 Suppl 3():49-55. PubMed ID: 27659411 [TBL] [Abstract][Full Text] [Related]
14. Evaluation of Gallium-68 prostate-specific membrane antigen, positron emission tomography/computed tomography (GA-68 PSMA PET/CT) in recurrent prostate cancer: a retrospective review of initial clinical experience at Tygerberg Hospital. Sangiwa BA; Burger C; Ellmann A Pan Afr Med J; 2024; 48():30. PubMed ID: 39220559 [TBL] [Abstract][Full Text] [Related]
15. The superior detection rate of total-body [ Wang Y; Dong L; Zhao H; Li L; Huang G; Xue W; Liu J; Chen R Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2484-2494. PubMed ID: 38514483 [TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. Morigi JJ; Stricker PD; van Leeuwen PJ; Tang R; Ho B; Nguyen Q; Hruby G; Fogarty G; Jagavkar R; Kneebone A; Hickey A; Fanti S; Tarlinton L; Emmett L J Nucl Med; 2015 Aug; 56(8):1185-90. PubMed ID: 26112024 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic performance of Rahbar K; Afshar-Oromieh A; Seifert R; Wagner S; Schäfers M; Bögemann M; Weckesser M Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2055-2061. PubMed ID: 30027419 [TBL] [Abstract][Full Text] [Related]
18. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. van Leeuwen PJ; Stricker P; Hruby G; Kneebone A; Ting F; Thompson B; Nguyen Q; Ho B; Emmett L BJU Int; 2016 May; 117(5):732-9. PubMed ID: 26683282 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. Eiber M; Maurer T; Souvatzoglou M; Beer AJ; Ruffani A; Haller B; Graner FP; Kübler H; Haberkorn U; Eisenhut M; Wester HJ; Gschwend JE; Schwaiger M J Nucl Med; 2015 May; 56(5):668-74. PubMed ID: 25791990 [TBL] [Abstract][Full Text] [Related]
20. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer. Sanli Y; Kuyumcu S; Sanli O; Buyukkaya F; İribaş A; Alcin G; Darendeliler E; Ozluk Y; Yildiz SO; Turkmen C Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]